Goldman Sachs
OCUL icon

Goldman Sachs’s Ocular Therapeutix OCUL Stock Holding History

Goldman Sachs’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,000
Closed -$46K – 5354
2019
Q3 		$46K Buy
+15,000
New +$67.1K ﹤0.01% 5050

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs's OCUL Position: Q2 2026 in Review

Goldman Sachs increased its Ocular Therapeutix (OCUL) stake by 59% in Q2 2026, buying an estimated $5.9M and bringing the position to 1,761,754 shares worth $17.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2783.

Goldman Sachs first reported a position in OCUL in Q2 2015 and has held it in 42 quarters since. The position peaked at $18.8M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Goldman Sachs held 1,761,754 shares of Ocular Therapeutix worth $17.3M as of Q2 2026.
  • Goldman Sachs bought 651,388 Ocular Therapeutix shares in Q2 2026, an estimated $5.9M.
  • Ocular Therapeutix made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2783 holding.
  • Goldman Sachs first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 42 quarters since.
  • Goldman Sachs's Ocular Therapeutix position peaked at $18.8M in Q4 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.